Name：HE Hongwei

Department：Department of Oncology

Tel: (8610)13691213210

Email:hehwei@imb.pumc.edu.cn

Education & Research Experience

Aug 2005-present: Research assistant/Research associate/Research Professor, vice director of Department of Oncology, Institute of Medicinal Biotechnology, CAMS&PUMC, Beijing, P. R. China, major in Microbiology & Biochemical Pharmacology.

Sep 2008-Jan 2010: Postdoc, School of medicine, Yale University in New Haven, Connecticut, Liver disease drug development and molecular pharmacology.

Nov 2006-Jan 2007: Visitor, Public Health Research Institute (PHRI) in Newark, New Jersey, advanced microarray technology training.

Sept 2002 – Jul 2005: Ph.D. in Tumor Molecular Pharmacology, Department of Oncology, Institute of Medicinal Biotechnology, CAMS&PUMC, Beijing, P. R. China

Research Field：Molecular pharmacology of tumor and liver diseases

Research Interests

Dr. He mainly has been engaged in the molecular pharmacology of tumor and liver diseases. He focus on the process of chronic hepatitis, liver fibrosis, cirrhosis and cancer, explores the new molecular mechanism in the process of disease occurrence and development, looks for novel potential drug targets, expounds the new mechanism of existing drugs, and try to develop new therapeutic strategies and targeted drugs.

Selected Publications

1. Zhang N, Zhao SS, Zhang YX, Wang YC, Shao RG, Wang JX*, He HW*. A novel biphenyl compound IMB-S7 ameliorates hepatic fibrosis in BDL rats by suppressing Sp1-mediated integrin αv expression. Acta Pharmacol Sin. 2020 May;41(5): 661- 669.

2. Ge MX, Liu HT, Zhang N, Niu WX, Lu ZN, Bao YY, Huang R, Yu DK*, Shao RG*, He HW*. Costunolide represses hepatic fibrosis through WWP2-mediated Notch3 degradation. Br J Pharmacol. 2020 Jan;177(2):372-387.

3. Ge MX, Niu WX, Ren JF, Cai SY, Yu DK, Liu HT, Zhang N, Zhang YX, Wang YC, Shao RG, Wang JX*, He HW*. A novel ASBT inhibitor, IMB17-15, repressed nonalcoholic fatty liver disease development in high-fat diet-fed Syrian golden hamsters. Acta Pharmacologica Sinica. 2019 Jul;40(7):895-907.

4. Zhao SS, Li NR, Zhao WL, Liu H, Ge MX, Zhang YX, Zhao LY, You XF, He HW*, Shao RG*. D-chiro-inositol attenuates cholestasis in bile duct ligated rats by improving bile acid secretion and attenuating oxidative stress, Acta Pharmacologica Sinica. 2018 Feb, 39(2): 213-221.

5. Ge M, Liu H, Zhang Y, Li N, Zhao S, Zhao W, Zhen Y, Yu J, He H*, Shao RG*. The anti-hepatic fibrosis effects of dihydrotanshinone I are mediated by disrupting the yes-associated protein and transcriptional enhancer factor D2 complex and stimulating autophagy. Br J Pharmacol. 2017 May; 174(10):1147-1160.

6. Zhao S, Li N, Zhen Y, Ge M, Li Y, Yu B, He H*, Shao RG*. Protective effect of gastrodin on bile duct ligation-induced hepatic fibrosis in rats. Food Chem Toxicol. 2015 Oct 21;86:202-207.

7. Dong-ke YU, Cai-xia ZHANG, Shuang-shuang ZHAO, Sheng-hua ZHANG, Hao ZHANG, Shi-Ying CAI, Rong-guang SHAO, Hong-wei HE*, The anti-fibrotic effects of epigallocatechin-3-gallate in bile duct-ligated cholestatic rats and human hepatic stellate LX-2 cells are mediated by the PI3K/Akt/Smad pathway. Acta Pharmacologica Sinica (2015) 36: 473–482.

8. Hongwei He, Albert Mennone, James L. Boyer, and Shi-Ying Cai. Combination of retinoic acid and ursodeoxycholic acid attenuates liver injury in bile duct ligated rats and human hepatic cells. Hepatology. 2011; 53(2):548-57.

Awards and Honors

2017 Chinese Pharmaceutical Association-Sanofi young biopharmaceutical Award

Academic Appointments

Member of anticancer drugs Committee of China anticancer association; Member of tumor pharmacology Committee of Chinese pharmacological Association